Anti-Nociceptive Role of Neuropeptide Y in the Nucleus Accumbens in Rats with Inflammation, an Effect Modulated by Mu- and Kappa-Opioid Receptors

JJ Li,LC Yu
DOI: https://doi.org/10.1080/10020070612331343204
2006-01-01
Abstract:Recent study in our laboratory showed that neuropeptide Y (NPY) plays an antinociceptive role in the nucleus accumbens (NAc) in intact rats. The present study was performed to further investigate the effect of NPY in nociceptive modulation in the NAc of rats with inflammation, and the possible interaction between NPY and the opioid systems. Experimental inflammation was induced by subcutaneous injection of carrageenan into the left hindpaw of rats. Infra-NAc administration of NPY induced a dose-dependent increase of hindpaw withdrawal latencies (HWLs) to thermal and mechanical stimulations in rats with inflammation. The anti-nociceptive effect of NPY was significantly blocked by subsequent intra-NAc injection of the Y1 receptor antagonist NPY28-36, suggesting an involvement of Y1 receptor in the NPY-induced anti-nociception. Furthermore, infra-NAc administration of the opioid antagonist naloxone significantly antagonized the increased HWLs induced by preceding infra-NAc injection of NPY, suggesting an involvement of the endogenous opioid system in the NPY-induced anti-nociception in the NAc during inflammation. Moreover, the NPY-induced anti-nociception was attenuated by following intra-NAc injection of the mu-opioid antagonist beta-funaltrexamine (beta-FNA), and kappa-opioid antagonist nor-binaltorphimine (nor-BNI), but not by delta-opioid antagonist naltrindole, indicating that mu- and kappa-opioid receptors, not a-opioid receptor, are involved in the NPY-induced anti-nociception in the NAc in rats with inflammation.
What problem does this paper attempt to address?